Depression is considered by WHO as the main contributor to global disability and it poses
dangerous threats to approximately all aspects of human life, in particular public and private …

Background Mood disorders are characterized by heterogeneity in severity, symptoms and
treatment response. The possibility of selecting the correct therapy on the basis of patient …

Antidepressant selection is largely a trial-and-error process. We used electronic health
record (EHR) data and artificial intelligence (AI) to predict response to four antidepressants …

The landscape of psychiatry is ever evolving and has recently begun to be influenced more
heavily by new technologies. One novel technology which may have particular application to …

Background Psychological therapies are effective for treating major depressive disorder, but
current clinical guidelines do not provide guidance on the personalization of treatment …

Hepatocellular Carcinoma (HCC), the most common primary liver cancer, is a significant
contributor to worldwide cancer-related deaths. Various medical imaging techniques …

Major depressive disorder (MDD) is the leading cause of disability worldwide, yet treatment
selection still proceeds via “trial and error”. Given the varied presentation of MDD and …

Aifred is a clinical decision support system (CDSS) that uses artificial intelligence to assist
physicians in selecting treatments for major depressive disorder (MDD) by providing …

Background: Approximately two-thirds of patients with major depressive disorder do not
achieve remission during their first treatment. There has been increasing interest in the use …

Clinical decision support systems (CDSS) augmented with artificial intelligence (AI) models
are emerging as potentially valuable tools in healthcare. Despite their promise, the …